ReviewJournal of veterinary pharmacology and therapeutics2022
Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.
Review in Journal of veterinary pharmacology and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 27 citations in OpenAlex.
- Lack of Effectiveness of Tramadol for Earlier Limb Weight-Bearing After Femoral Head and Neck Excision in 38 Dogs.Animals : an open access journal from MDPI · 2026Article
- Phytocompounds in Precision Dermatology: COX-2 Inhibitors as a Therapeutic Target in Atopic-Prone Skin.Biomolecules · 2025Article
- New Gel Approaches for the Transdermal Delivery of Meloxicam.Gels (Basel, Switzerland) · 2025Review
- Article
- Evaluation of cats treated with robenacoxib after gastrointestinal surgery.Journal of feline medicine and surgery · 2024Article
- Evaluation of the analgesic efficacy of grapiprant compared with robenacoxib in cats undergoing elective ovariohysterectomy in a prospective, randomized, masked, non-inferiority clinical trial.Journal of feline medicine and surgery · 2024Article
- Design, Synthesis, Biological Evaluation, and Molecular Docking Study of 4,6-Dimethyl-5-aryl/alkyl-2-[2-hydroxy-3-(4-substituted-1-piperazinyl)propyl]pyrrolo[3,4-Pharmaceuticals (Basel, Switzerland) · 2023Article
- Effects of Temperature on Plasma Protein Binding Ratios (PPBRs) of Enrofloxacin and Ciprofloxacin in Yellow Catfish (Animals : an open access journal from MDPI · 2023Article
- Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration.Journal of veterinary pharmacology and therapeutics · 2022Article
- Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.Journal of veterinary pharmacology and therapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robenacoxib is a veterinary-approved non-steroidal anti-inflammatory drug (NSAID) of the coxib group. It possesses anti-hyperalgesic, anti-inflammatory and anti-pyretic properties. Robenacoxib inhibits the cyclooxygenase (COX)-2 isoform of COX selectively (in vitro IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.